New drug cocktail shows promise for liver cancer in hepatitis b patients

NCT ID NCT04180072

Ongoing Disease control Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, and researchers monitor tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to: If successful, this could offer a new treatment option for advanced liver cancer in people with chronic hepatitis B, potentially shrinking tumors and extending life.
What could go wrong: This is a small, single-arm trial with no comparison group, so results may not be definitive. The drugs can cause serious side effects like liver damage or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

Chang Gung Memorial Hospital

Linkou District, Taiwan
China Medical University Hospital

Taichung, Taiwan
Mackay Memorial Hospital

Taipei, Taiwan
National Cheng Kung University Hospital

Tainan, Taiwan
National Taiwan University Hospital

Taipei, Taiwan
Taichung Veterans General Hospital

Taichung, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.